Korro Bio Inc (KRRO) FinancialsKRROKorro Bio Inc

Evaluating the bottom line, Korro Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -97.69%, provide a clear picture of how effectively KRRO converts its operational activities into shareholder value.

In the context of the broader market, KRRO competes directly with industry leaders such as MENS and PLX. With a market capitalization of $195.56M, it holds a significant position in the sector. When comparing efficiency, KRRO's gross margin of N/A stands against MENS's N/A and PLX's -11314.71%. Such benchmarking helps identify whether Korro Bio, Inc. is trading at a premium or discount relative to its financial performance.

Korro Bio's financial performance shows significant losses, with a net income of -50,042,000 USD in Q4 2025 and a forward P/E ratio of 0, indicating no earnings expected in the near term. The gross margin is currently at 100% for the last reported quarter, but this is offset by the lack of revenue in Q1 2026.